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A b s t r a c t  
Gastroparesis is a syndrome characterized by delayed gastric emptying, in the absence of 
mechanical obstruction of the stomach. Diabetes mellitus (DM) is responsible for almost one third of 
cases of gastroparesis. Gastroparesis typically develops after at least 10 years of evolution of DM, 
and often is associated with other complications. The present study aimed to investigate the safety, 
reliability of Metformin and possible drug interaction with Itopride when they were administered as 
combination treatment. The study was conducted on healthy Wistar and streptozotocin induced 
diabetic rats.  A simple and sensitive high performance liquid chromatographic method was 
developed for the simultaneous estimation of Metformin and Itopride in rat plasma and also to 
estimate possible pharmacokinetic parameters of these drugs after oral administration. There was 
no significant difference in the Metformin alone and combination with Itopride and Itopride alone and 
combination with Metformin on day 1 and day 8 respectively. There is no significant change in tmax, 
cmax, AUC (0 ă t) and AUC (o-inf), tó, Cl/f and V/f on day 1 and day 8 respectively in both diabetic and 
healthy rats. From the above results it can be concluded that the concurrent administration of these 
two drugs have potential benefit in the treatment of Diabetes and Gastroparesis. In addition, due to 
their insignificant pharmacokinetic interaction the combinational therapy can be safe and highly 
advantageous in Gastro paresis patients with diabetes.   
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Introduction 
Diabetes mellitus is a chronic metabolic disorder characterized by 
persistent hyperglycemia, altered metabolism of lipids, 
carbohydrates, proteins and an increased risk of complications 
from vascular diseases [1-3]. Diabetes occur either due to 
decreased synthesis of insulin (Type-1) or due to defective 
secretion of insulin from beta cells of islets of langerhans (Type-2) 
[4]. Literature study reveals that diabetic patients developing 
multiple pathology such as fungal infection, cardiovascular 
disorders, nephropathy, retinopathy, neuropathy, sexual 
impotence, hyperacidity, constipation and respiratory tract 
infections [5]. Gastroparesis is a syndrome characterized by 
delayed gastric emptying, in the absence of mechanical obstruction 
of the stomach. The cardinal symptoms include postprandial 
fullness, nausea, vomiting, and bloating. Diabetes mellitus (DM) is 
responsible for almost one third of cases of gastroparesis. 
Gastroparesis typically develops after at least 10 years of evolution 
of DM, and often is associated with other complications. It may 
cause severe symptoms and result in nutritional compromise, 
impaired glucose control and a poor quality of life.. Symptoms 
connected to gastroparesis are reported by 5 to 12% of DM.  
Drug interactions have been reported to be the fourth to sixth 
leading cause of death in hospitalized patients in United States [6]. 
Drugădrug interactions may occur when more than one drug is 
administered in a patient to treat a single ailment or multiple 
ailments. The concomitant use of several drugs is often desired to 
obtain a therapeutic objective or to treat co-existing diseases. 
Simultaneous use of several drugs may lead to drugădrug 
interactions, the net result of interaction may be enhanced or 
diminished effects of one or both the drugs or the appearance of 
anew effect that is not seen with either drug alone [7]. There are 
several diseases those require lifelong treatment such as diabetes 
and hypertension. Patients with such diseases will often need to be 
administered drugs for treatment of other co-existing diseases, 
either for a short period or lifelong [8]. Metformin has an 
oral bioavailability of 50ă60% under fasting conditions, and is 
absorbed slowly. Peak plasma concentrations (Cmax) are reached 
within one to three hours of taking immediate-release Metformin 
and four to eight hours with extended-release 
formulations. The plasma protein binding of Metformin is negligible, 
as reflected by its very high apparent volume of distribution (300ă
1000 l after a single dose). Steady state is usually reached in one 
or two days. Metformin is metabolized  [9] and it is excreted 
unchanged in the urine and does not undergo hepatic metabolism 
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(no metabolites have been identified in humans) or biliary 
excretion9, 10. Itopride undergoes rapid and extensive absorption 
with levels of Itopride peaking in the blood plasma after only 35 
minutes. Itopride is primarily eliminated via the kidneys having 
an elimination half-life of approximately 6 hours. In the present 
study, two diseases (diabetes and Gastroparesis) those may co-
exist and require chronic treatment with the possibilities of 
occurrences of interactions between the concurrently used drugs. 
Materials and methods 
Materials 
Drugs and Chemicals 
Metformin and Itopride were procured from Matrix laboratories as a 
gift sample. Streptozotocin (STZ) was purchased from Sigma 
Chemical Co. The glucose estimation (GOD- POD) kit (excel 
diagnostic, Hyderabad) was procured from drug store. All HPLC 
grade solvents (methanol and water) were procured from finar 
chemicals Ltd., Ahmadabad. All chemicals used were analytical 
grade. 
Animal study  
Healthy Wistar rats were (Weighing 200-220 g) selected for this 
study, all the animals were healthy during the period of the 
experiment. All efforts were made to maintain the animals under 
controlled environmental conditions (Temperature 250C, Relative 
Humidity 45% and 12 h alternate light and dark cycle) with 100 % 
fresh air exchange in animal rooms, uninterrupted power and water 
supply.  Rats were fed with standard diet and water ad libitum. The 
protocol of animal study was approved by the institutional animal 
ethics committee. 
Induction of Experimental Diabetes 
Male Wistar rats (200-250gms) were fasted for 16 hours before the 
induction of diabetes with Streptozotocin (STZ), a valuable agent 
for induction of Type-1 Diabetes mellitus. Animals (n=6) were 
injected intraperitoneal with 0.22 - 0.25ml of freshly prepared 
solution of STZ (60 mg / ml in 0.01 m citrate buffer, pH 4.5) at a 
final dose of 60mg / kg body wt. The diabetic state was assessed 
in STZ - treated rats by measuring the non-fasting serum glucose 
concentration after 48 hours. Only rats with serum glucose levels 
greater than 300 mg / dl were selected and used in this 
experiment. 
Study Design  
The rats were grouped as follows 
Group I : Metformin alone in single dose / day in diabetic 
rats.  
Group II : Itopride alone in single dose / day in diabetic 
rats.  
Group III : Itopride alone in single dose / day in normal 
healthy rats 
Group IV : Metformin and Itopride concomitant 
administration in diabetic rats as a  
                                    single dose / day. 
Collection of blood samples  
After administration of the drugs, blood samples of 0.5 ml were 
drawn from each anesthetized (isoflurane) rat at pre-determined 
time intervals was collected from the retro-orbital plexus using a 
capillary tube into pre-labeled eppendorf tubes containing 10% of 
K2EDTA anticoagulant     (20 μL). The time intervals for the sample 
collection were 0 (Pre dose), 0.5, 1, 2, 4, 6, 8 and 24 hrs (post 
dose), Equal amount of saline was administered to replace blood 
volume at every blood withdrawal time.  
Plasma was obtained by centrifuging blood samples by using 
cooling centrifuge (REMI ULTRA) at 3000 rpm for 5 minutes. The 
obtained plasma samples were transferred into pre-labeled micro 
centrifuge tubes and stored at î20ĈC until bio analysis of 
pharmacokinetic and pharmacodynamic parameters. As described 
above, all the procedures were followed on day 8 also. 
Pharmacokinetic parameters were calculated by non-
compartmental analysis by using     Win Nonlin® 5.1 software. 
Concentrations obtained from the above bio-analytical method 
were 
Compiled [12,13]. 
Method of analysis  
Preparation of plasma samples for HPLC analysis  
Rat plasma (0.5 ml) samples were prepared for chromatography by 
precipitating proteins with 2.5 ml of ice-cold absolute ethanol for 
each 0.5 ml of plasma. After centrifugation the ethanol was 
transferred into a clean tube. The precipitate was re suspended 
with 1 ml of Acetonitrile by vortexing for 1 min. After centrifugation 
(5000 ă 6000 rpm for 10 min), the Acetonitrile was added to the 
ethanol and the organic mixture was taken to near dryness by a 
steam of nitrogen at room temperature. Samples were 
reconstituted in 200 μ1 of mobile phase was injected for HPLC 
analysis. 
For HPLC An Inertsil ODS 3V, 250x4.6 mm, C18 column with 5 μm 
particle size and the Mobile Phase consisting of phosphate buffer 
and Methanol Ratio 70:30 respectively. The flow rate was 0.8 
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ml/min and the effluents were monitored at 215 nm. Internal 
standard Phenformin was used. The retention time of internal 
standard (Phenformin) Metformin and Itopride in plasma were 
9.8min, 7.2min and 3.3min respectively[14]. 
Standard calibration curve of Metformin and Itopride in 
rat plasma         
Different concentration (0.05, 0.1, 0.5, 1, 5, 10, 20, 40   øg/ml) of 
Metformin, Itopride   in plasma were prepared for calibration curve. 
The samples were treated as above for protein precipitation 
method and peak areas of Metformin and Itopride were noted 
down. The peak area ratios obtained at different concentrations of 
the Metformin and Itopride were plotted using     UV ă Vis detector 
at 215 nm.  
Pharmacokinetic analysis  
Plasma concentration versus time data was analyzed using 
standard non-compartment analysis.AUC0-t refers to the AUC from 
0 to 24 hrs, which was determined by linear trapezoidal rule and 
AUC0-α refers to the AUC from time at zero hours to infinity.  
The AUC0-α was calculated using the formula AUC0-t + [Clast/K] 
where C last is the concentration in μg/ml at the last time point and 
K is the elimination rate constant. 
Various pharmacokinetic parameters like area under the curve 
[AUC], elimination half life [tó]. Volume of distribution (V/f) total 
clearance (Cl/f) and mean residence time for each subject using a 
non-compartmental analysis by using Win Nonlin® 5.1 software. 
Statistical analysis  
Statistical comparisons for the pharmacokinetic ă 
pharmacodynamic study among, Metformin, Itopride, Itopride alone 
and in combination groups and plasma concentration ă response 
study among concentrations and time were carried out with 
studentÊs paired T-Test a value of P<0.05 was considered to be 
statistically significant. Data were reported as mean ± S.E.M linear 
regressions were used to determine the relationship between total 
plasma concentrations and pharmacokinetic and 
pharmacodynamic parameters. The mean concentration versus 
time profile of Metformin and Itopride in rat plasma is shown in 
Figures 1, 2, 3, 4, 5 & 6 1412. 
Results and Discussion 
 
   Table 1: Mean μ S.E.M, pharmacokinetic parameters of Metformin alone and in Combination with Itopride on day 1 
parameters Metformin alone Metformin combination with Itopride 
Level of 
significance(p<0.05) 
Cmax (øg) 25.74μ0.39 26.03μ0.12 NS 
tmax (h) 2μ0 2μ0 NS 
AUCo-t (øg/ml/h) 272.45μ0.74 276.37μ0.52 NS
AUCo-inf (øg /ml/h) 368.82μ2.50 356.15μ1.85 NS
T1/2 (h) 11.56μ0.28 10.64μ0.09 NS
CL/f(ml/h/kg) 2.196μ0.015 2.23μ0.01 NS
V/F(ml/kg) 40.63μ0.26 37.56μ0.25 NS
NS-Not significant 
 
Table 2: Mean μS.E.M, pharmacokinetic parameters of Metformin alone and in Combination with Itopride on day 8 
parameters Metformin alone Metformin combination 
with Itopride 
Level of 
significance(p<0.05) 
Cmax (øg) 31.92μ0.22 32.41μ0.1 NS
tmax (h) 2μ0 2μ0 NS
AUCo-t (øg/ml/h) 337.36μ0.38 343.38μ0.49 NS
AUCo-inf (øg /ml/h) 396.36μ0.63 413.49μ0.74 NS
T1/2 (h) 8.496μ0.024 9.08μ0.018 NS
CL/f(ml/h/kg) 1.961μ0.009 1.92μ0.05 NS
V/F(ml/kg) 26.67μ1.27 27.89μ0.32 NS
NS- Not significant 
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Table 3: Mean μ S.E.M, pharmacokinetic parameters of Itopride in diabetic versus healthy male Wistar rats on day 1 
Parameters Itopride in diabetic       
rats 
Itopride in healthy              
rats 
Level of 
significance(p<0.05) 
Cmax (øg) 3.92μ0.03 2.72μ0.03 NS 
tmax (h) 2μ0 2μ0 NS 
AUCo-t (øg/ml/h) 33.49μ0.20 21.9μ0.118 NS 
AUCo-inf (øg /ml/h) 52.23μ1.36 27.49μ0.808 NS 
T1/2 (h) 15.22μ0.49 12.03μ1.11 NS 
CL/f(ml/h/kg) 15.475μ0.401 26.71μ0.18 NS 
V/F(ml/kg) 359.16μ2.38 497.65μ3.09 NS 
NS- Not significant 
 
Table 4: Mean μS.E.M, pharmacokinetic parameters of Itopride in diabetic versus healthy male Wistar rats on day 8 
Parameters Itopride in diabetic       rats Itopride in non 
diabetic              rats 
Level of 
significance(p<0.05) 
Cmax (øg) 4.80μ0.04 3.65μ0.06 NS
tmax (h) 2μ0 2μ0 NS
AUCo-t (øg/ml/h) 44.11μ0.225 38.22μ0.09 NS
AUCo-inf (øg /ml/h) 61.57μ0.43 67.37μ0.336 NS
T1/2 (h) 12.49μ0.186 48.92μ0.0908 NS
CL/f(ml/h/kg) 13.01μ0.08 11.58μ0.04 NS
V/F(ml/kg) 255.8μ2.192 346.6μ0.639 NS
NS- Not significant 
 
  Table 5: Mean μ S.E.M, pharmacokinetic parameters of Itopride alone and in Combination with Metformin in diabetic rats on day 1 
Parameters Itopride alone  Itopride with Metformin Level of significance (p<0.05)
Cmax (øg) 3.92μ0.03 3.783μ0.02 NS
tmax (h) 2μ0 2μ0 NS
AUCo-t (øg/ml/h) 33.49μ0.016 31.62μ0.20 NS
AUCo-inf (øg /ml/h) 52.33μ1.37 42.16μ0.52 NS
T1/2 (h) 15.22μ0.49 11.57μ0.27 NS
CL/f(ml/h/kg) 15.475μ0.40 19.03μ0.266 NS
V/F(ml/kg) 359.16μ2.233 337.66μ4.25 NS
NS- Not significant 
 
Table 6: Mean μS.E.M, pharmacokinetic parameters of Itopride alone and in Combination with Metformin in Diabetic rats on day 8 
Parameters Itopride alone  Itopride with Metformin Level of significance (p<0.05)
Cmax (øg) 4.80μ0.04 4.615.μ0.04 NS
tmax (h) 2μ0 2μ0 NS
AUCo-t (øg/ml/h) 33.5μ0.2253.2 41.6μ0.25 NS
AUCo-inf (øg /ml/h) 52.6μ0.43 59.76μ0.88 NS
T1/2 (h) 15.23μ0.18 12.89μ0.29 NS
CL/f(ml/h/kg) 15.43μ0.08 13.48μ0.03 NS
V/F(ml/kg) 358.65μ2.16 272.1μ2.26 NS
NS- Not significant 
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Figure 1: Mean Plasma concentrations (øg/ml) of Metformin alone and combination with Itopride on day 1 in Diabetic male Wistar rats (n=6)  
  
 
 
Figure 2: Mean Plasma concentrations (øg/ml) of Metformin alone and combination with Itopride on day 8 in Diabetic male Wistar rats (n=6) 
 
 
 
Figure 3: Mean plasma concentrations (øg/ml) of Itopride in healthy rats versus diabetic male Wistar rats on day 1(n=6) 
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Figure 4: Mean plasma concentrations (øg/ml) of Itopride in healthy rats versus diabetic male Wistar rats on day 8(n=6) 
 
Figure 5: Mean plasma concentrations (øg/ml) of Itopride alone and combination with Metformin on day 1 in diabetic male Wistar rats (n=6) 
 
Figure 6: Mean plasma concentrations (øg/ml) of Itopride alone and combination with Metformin on day 8in diabetic male Wistar rats (n=6) 
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In the present study, Metformin is completely absorbed after oral 
administration with peak plasma concentration of 24.34±0.3μg/ml 
after 2hrs of dosing on day 1. In combination with Metformin and 
Itopride on day 1, the peak plasma concentration of Metformin 
26.03±0.12μg/ml occurred 2 hr after dosing. There was no 
significant increase in peak plasma concentration levels. Similarly 
Itopride is completely absorbed after oral administration with peak 
plasma concentration 3.92±0.03μg/ml occurred 2hr after dosing on 
day 1 in combination with Metformin and Itopride on day 1. The 
peak plasma concentration of Itopride 3.783±0.02 μg/ml occurred 
2hr after dosing. There was no significant increase in the peak 
plasma concentration levels similarly on day 8 of Metformin alone 
and with combination of Metformin with Itopride on day 8. Peak 
plasma concentration are 31.92±0.22 μg/ml and 32.41±0.10μg/ml 
respectively similarly Itopride on day 8 and combination with 
Metformin concentrations are 4.80 ± 0.04 μg/ml and 4.615 ± 
0.04μg/ml respectively. There was no significant difference in peak 
plasma concentration on day 8 (P>0.05).  The results were showed 
in from figure 1 to 6. 
A significant differences was observed between diabetic and 
healthy Itopride treated rats on day 1 and day 8 respectively 
(P<0.05) on oral administration of Itopride alone and with 
combination of Metformin. With Itopride on day 1 showed a 2% 
increase in the AUC0ăt of Metformin compared to combinational 
treatment similarly. Itopride on day 1 and with combination 
Metformin with Itopride on day 1 administration resulted in an 
increase in the AUC 0 ă24 of Itopride compared with combinational 
treatment. Similarly on day 8 of Metformin and Itopride in 
combination treatment were 1.65% and 2.8% increase in the AUC0 
ă 24 respectively. 
The mean AUC0 ă t of Itopride in diabetic (HL) rats was 33.49± 0.20 
μg/ml /h and 44.11 ±0.22 μg/ml/h which was reduced to 
21.9±0.11μg/ml/h and 38.22 ±0.09μg/ml/h Itopride in healthy rats 
on day 1 and day 8 treatment (P<0.05) respectively. There was 
slight decrease in the clearance (CL/F) rate of Metformin in 
combination compared with Metformin alone by 2.52% and 0.92% 
on day 1 and day 8 respectively. Similarly there was slight 
decrease in the clearance (CL/F) of Itopride in combination 
compared with Itopride alone by 4.92% on day 1. On day 8 a slight 
increase in the clearance (CL/F) of Itopride in combination 
compared with Itopride alone by 4.6%.  
The half life was similar with alone and combination treatment on 
day 1 and day 8. All these changes were not statistically significant 
(P>0.05).  
The mean clearance (C1/F) was 15.475±0.401(ml/h/kg) and 
26.71±0.18(ml/h/kg) which was reduced to 13.01±0.08(m1/h/kg) 
and 11.58±0.042(m1/h/kg) upon treatment of Itopride in diabetic 
rats and healthy rats on day 1 and day 8 respectively.  
Volume of distribution was increased 3.8% and 1.72% in Metformin 
alone compared with Metformin and Itopride on day 1 and day 8 
respectively. similarly Itopride in diabetic rats and healthy rats 
resulted 359.16 and 497.65 on day 1 respectively Itopride alone on 
day 1 and combination with Metformin on day 1 administration 
resulted in 1.5% increases of volume distribution (ml/kg) in alone 
Itopride group treated rats similarly on day 8 administration 
resulted in 5.5 increases of volume of distribution in alone Itopride 
treated rats. The results were showed from table 1to 6.  
Conclusion 
The present study results suggest that the Concomitant 
administration of Metformin with Itopride has no significant 
pharmacokinetic interactions at absorption, distribution metabolism 
and excretion so it can be concluded that the concomitant 
administration of Metformin and Itopride is effective and safe for 
treatment, thus suggesting cautionary use in diabetic and 
Gastroparesis condition.  
 
 
 
References 
 
[1]. Bastaki S. Diabetes mellitus and its 
treatment. Int. j . Diabetes and 
Metabolism. 2005; 13: 111-134. 
[2]. Murthy T, Mayuren C, Krishna M, Reddy 
T. Study of interaction between 
amlodipine besylate and gliclazide in 
healthy rats. Int J Pharm Biol Sci. 2008;  
2: 139-42. 
[3]. Swami AM, Shetty SR, Kumar S, Rao N. 
A study on drug-drug interaction of 
roxithromycin and antidiabetic drugs. 
Indian Drugs. 2005; 42: 808-13. 
[4]. Satyanarayana S, Krishnaiah Y, Eswar 
Kumar K, Elisha Raj I, Kanti Kiran V. 
Influence of Quinidine, Selegiline and 
Amphotericin-B on the 
pharamacokinetics and 
pharmacodynamics of Tolbutamide in 
Rabbits. Indian drugs. 1998; 35: 640-4. 
[5]. Rambhimaiah S, Suresh D, Gupta V, 
Ravi Prakash P, Srinivas Rao P. 
Influence of metronidazole on the 
hypoglycaemic effect of tolbutamide in 
healthy albino rabbits. Indian drugs. 
2003; 40: 535-8. 
[6]. Palmer KJ, Brogden RN. Gliclazide: An 
update of its pharmacological properties 
and therapeutic efficacy in non-insulin-
dependent diabetes mellitus. 
Drugs. 1993; 46(1): 92-125. 
[7]. Kohler G, Bode-Boger S, Busse R, 
Hoopmann M, Welte T, Boger R.. 
Vunnam et al.  International Journal of Drug Delivery 7 (1) 52-59 [2015] 
 
 
  
PAGE | 59 |
 
Elements of clinical pharmacy, 6th edi. 
2004. BS Shah Prakashan Ahmedbad. 
[8]. Pentikäinen P. Bioavailability of 
metformin. Comparison of solution, 
rapidly dissolving tablet, and three 
sustained release products. IJCPT. 
1986; 24: 213-20. 
[9]. Heutling D, Schulz H, Nickel I, Kleinstein 
J, Kaltwasser P, Westphal S, 
Mittermayer F, Wolzt M, Krzyzanowska 
K, Randeva H. Asymmetrical 
dimethylarginine, inflammatory and 
metabolic parameters in women with 
polycystic ovary syndrome before and 
after metformin treatment. j clinical 
endocrinology metabolism. 2008; 93: 82-
90. 
[10]. Scheen AJ. Clinical pharmacokinetics of 
metformin. Clin pharmacokinetics. 1996; 
30: 359-71. 
[11]. Nagy CF, Kumar D, Perdomo CA, 
Wason S, Cullen EI, Pratt RD. 
Concurrent administration of donepezil 
HCl and sertraline HCl in healthy 
volunteers: assessment of 
pharmacokinetic changes and safety 
following single and multiple oral doses. 
Bri. j clin ph cology. 2004; 58: 25-33. 
[12]. Davit BM, Nwakama PE, Buehler GJ, 
Conner DP, Haidar SH, Patel DT, Yang 
Y, Lawrence XY, Woodcock J. 
Comparing generic and innovator drugs: 
a review of 12 years of bioequivalence 
data from the United States Food and 
Drug Administration. Annals of 
Pharmacotherapy. 2009; 43: 1583-97. 
[13]. Meredith P. Bioequivalence and other 
unresolved issues in generic drug 
substitution. Clinical therapeutics. 2003; 
25: 2875-90.  
[14]. Vunnam RR, Sriharsha S, Rajesham V. 
A new validated RP-HPLC method for 
simultaneous estimation of Itopride and 
Metformin HCl in bulk formulation. Der 
Pharmacia Lettre. 2014; 6 (6):76-81 
 
  
 
 
